Annexon (ANNX) Stock Price, News & Analysis

Company Overview

Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies for diseases driven by activation of the classical complement pathway, an immune-system mechanism involved in inflammation and tissue damage. The company’s approach is designed to selectively inhibit complement activity while preserving other parts of the immune response.

Annexon’s pipeline has included ANX005, an investigational monoclonal antibody that targets C1q, an initiating protein in the classical complement pathway. The company has studied ANX005 in neurological and autoimmune conditions, including Guillain-Barré syndrome. Annexon has also developed other complement-focused candidates, including ANX007, an investigational ophthalmic treatment designed to inhibit C1q activity in the eye, and ANX1502, an orally administered complement inhibitor.

Founded in 2011, Annexon is headquartered in South San Francisco, California, and focuses on developing medicines for patients with complement-mediated disorders. The company’s operations and clinical development activities are directed primarily toward advancing its investigational pipeline through clinical testing and regulatory evaluation. Douglas Love serves as the company’s chief executive officer.

Key Stats

• Today's Range: $4.11 to $4.27
• 50-Day Range: $3.64 to $5.60
• 52-Week Range: $2.54 to $7.18
• Volume: 4.02 million shs
• Average Volume: 3.48 million shs
• Market Capitalization: $794.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.29
• Consensus Rating: Hold

Annexon Stock Analysis - MarketRank™

Annexon scored higher than 71% of companies evaluated by MarketBeat, and ranked 184th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Annexon has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Annexon has a consensus price target of $15.29, representing about 264.8% upside from its current price of $4.19.

Amount of Analyst Coverage

Annexon has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Annexon are expected to grow in the coming year, from ($1.05) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annexon is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annexon is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annexon has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.33% of the float of Annexon has been sold short.

Short Interest Ratio / Days to Cover

Annexon has a short interest ratio ("days to cover") of 11.68, which indicates bearish sentiment.

Change versus previous month

Short interest in Annexon has recently increased by 2.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annexon does not currently pay a dividend.

Dividend Growth

Annexon does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.69

News Sentiment

Annexon has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Annexon this week, compared to 4 articles on an average week.

Search Interest

12 people have searched for ANNX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

MarketBeat Follows

3 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $99,829.00 in company stock, which represents 0.0126% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Annexon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,829.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.31% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Annexon has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ANNX
• CIK: 1528115
• Web: www.annexonbio.com
• Phone: 650-822-5500
• Fax: 650-636-9773
• Employees: 92
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Annexon: $15.29
• High Price Target: $27.00
• Low Price Target: $3.00
• Potential Upside/Downside: +264.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$206.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -106.15%
• Return on Assets: -79.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 5.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 2.95

Miscellaneous

• Outstanding Shares: 189,580,000
• Free Float: 170,033,000
• Market Cap: $794.34 million
• Optionable: Optionable
• Beta: 1.32